Long-acting somatostatin analogues provide significant beneficial effect in patients with refractory small bowel angiodysplasia: Results from a proof of concept open label mono-centre trial
about
Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre.Multicentre, open-label, randomised, parallel-group, superiority study to compare the efficacy of octreotide therapy 40 mg monthly versus standard of care in patients with refractory anaemia due to gastrointestinal bleeding from small bowel angiodysOctreotide as an adjunct in the management of arterial gastrointestinal bleeding: Should it be considered in refractory cases of obscure origin?Overview of small bowel angioectasias: clinical presentation and treatment options.Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study.Successful treatment of refractory midgut bleeding with ocreotide and corticosteroids in a dialysis patient with suspected sarcoidosis.
P2860
Long-acting somatostatin analogues provide significant beneficial effect in patients with refractory small bowel angiodysplasia: Results from a proof of concept open label mono-centre trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Long-acting somatostatin analo ...... t open label mono-centre trial
@en
type
label
Long-acting somatostatin analo ...... t open label mono-centre trial
@en
prefLabel
Long-acting somatostatin analo ...... t open label mono-centre trial
@en
P2093
P2860
P356
P1476
Long-acting somatostatin analo ...... t open label mono-centre trial
@en
P2093
Barry Hall
Grainne Holleran
Niall Breslin
P2860
P356
10.1177/2050640614559121
P577
2015-11-05T00:00:00Z